Dingli Sarah, Rothweiler Paul, Binder Moritz, Cook Joselle, Gertz Morie A, Hayman Suzanne, Kapoor Prashant, Kourelis Taxiarchis, Kumar Shaji K, Siddiqui Mustaqeem, Warsame Rahma, Lin Yi, Erdman Arthur G, Dingli David
Earl E. Bakken Medical Devices Center, Department of Mechanical Engineering, College of Science and Engineering, University of Minnesota, Twin Cities, MN, USA.
Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Blood Cancer J. 2025 May 7;15(1):90. doi: 10.1038/s41408-025-01280-2.
Changes in metabolic activity in tumor cells is one of the hallmarks of cancer. Cancer cells exhibit the Warburg effect with high glucose consumption for their energy needs. This provides the basis for imaging using F-2-deoxy-D-glucose for positron emission tomography to assess tumor burden and response to therapy. We postulated that metabolically active tumors may compete with the brain for glucose uptake and evaluated glucose uptake in the brain and liver in patients with multiple myeloma in various states of response and relapse. The ratio of brain to liver glucose activity (B2LR) mirrors disease activity in myeloma, predicts the presence of extramedullary disease and is also predictive of a short response to chimeric antigen receptor T cell therapy. Patients with a low B2LR also have an inferior survival compared to patients with persistently higher B2LR values. Our simple metabolic ratio has prognostic implications in myeloma and other tumors.
肿瘤细胞代谢活性的变化是癌症的标志之一。癌细胞表现出瓦伯格效应，为满足能量需求而大量消耗葡萄糖。这为使用F-2-脱氧-D-葡萄糖进行正电子发射断层扫描成像以评估肿瘤负荷和对治疗的反应提供了基础。我们推测，代谢活跃的肿瘤可能会与大脑竞争葡萄糖摄取，并评估了处于不同缓解和复发状态的多发性骨髓瘤患者大脑和肝脏中的葡萄糖摄取情况。脑与肝葡萄糖活性比（B2LR）反映了骨髓瘤的疾病活动情况，可预测髓外疾病的存在，也可预测嵌合抗原受体T细胞疗法的短期反应。与B2LR值持续较高的患者相比，B2LR较低的患者生存率也较低。我们这个简单的代谢比值对骨髓瘤和其他肿瘤具有预后意义。
